AKT1 and breast carcinoma: The combination of neratinib plus fulvestrant was also shown to potently inhibit cancer cell growth; downregulate ER reporter activity, P-AKT, and P-ERK; and reduce cyclin D1 mRNA and protein levels in ER+/HER2+ breast cancer cell lines51.